Innovative Approaches to the Treatment of Neovascular Retinal Diseases: A Podcast Series

1.50 CME
1.50 ABO MOC
90 MINS
$0 FEE
SAVE
Innovative Approaches to the Treatment of Neovascular Retinal Diseases: A Podcast Series

Overview

Provider Statement

This continuing medical education activity is provided by Vindico Medical Education.


Support Statement

This activity is supported by an educational grant from Genentech, Inc.


Activity Description

The integration of intravitreal anti-vascular endothelial growth factor therapies into treatment algorithms for the management of neovascular retinal diseases has provided significant visual outcome gains for these patients. The effectiveness of current treatment algorithms varies based on treatment protocol, number of therapy injections, and patient adherence. However, suboptimal responses to therapy along with loss of patient adherence from treatment burden has defined a need for the development of novel treatments and sustained delivery options for the management of neovascular retinal diseases. Within this 6-part podcast series, experts in the field evaluate the latest safety and efficacy findings pertaining to emerging therapies that may advance the treatment of neovascular diseases, as well as provide discussion on how these emerging therapies may be incorporated into real-world practice.


Target Audience

The intended audience for this activity is ophthalmologists, retina specialists, and other health care professionals involved in the management of patients with neovascular retinal disorders.


Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Appraise new science regarding the long-term efficacy of current treatments for neovascular retinal diseases.
  • Summarize new evidence about emerging therapies that may advance the treatment of neovascular retinal diseases.
  • Assess the safety of new advances for the treatment of neovascular retinal diseases and how they can be incorporated into real-world practice.
  • Incorporate evidence into practice regarding visual and anatomic outcomes produced by available and emerging anti-VEGF agents for the treatment of neovascular age-related macular degeneration.

Activity Chair

Carl D. Regillo, MD, FACS
Director, Wills Eye Retina Service
Professor of Ophthalmology
Thomas Jefferson University
Mid Atlantic Retina
Philadelphia, PA


Faculty

Jeffrey S. Heier, MD
Director, Retina Service
Co-President & Medical Director
Ophthalmic Consultants of Boston
Boston, MA

Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA

Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Retina Consultants of America
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX


Reviewer

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Accreditation

Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.


Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABOSuccessful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning requirements for the American Board of Ophthalmology’s Maintenance of Certification (ABO MOC) program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting MOC credit. Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn MOC credits equivalent to the amount of CME credits claimed for the activity. The CME activity provider will submit learner completion information to the ACCME for the purpose of granting ABO MOC credits within 30 days of activity completion.

This enduring material is approved for 1 year from the date of original release, June 30, 2020, through June 29, 2021.


How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objective, answer the pretest question, listen to the content, and complete the posttest and evaluation. Provide only one (1) correct answer for the question. A satisfactory score is defined as answering 66% of the posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ Certificate.


Disclosures

In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. An individual has a relevant financial relationship if he or she has a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.

Faculty report the following relationship(s)

Jeffrey S. Heier, MD
Consulting Fee: 4D Molecular Therapeutics, Adverum, Aerie, Aerpio, Aldeyra, Alkahest, Allegro, Allergan, Alzheon, Apellis, Array, AsclepiX, Chengdu Kanghong, Eloxx, Galimedix, Genentech/Roche, Generation Bio, Gyroscope, Interface, iRenix, Janssen, jCyte, Kala, Kodiak, NGM Biopharmaceuticals, Notal Vision, Novartis, Ocular Therapeutix, Oculis, Omeicos, Orbit, Regeneron, Regenxbio, Retrotope, Santen, SciFluor, Shire, Stealth BioTherapeutics, Voyant
Contracted Research: Aerpio, Apellis, Chengdu Kanghong, Clearside, Genentech/Roche, Genzyme, Gyroscope, Hemera, Janssen, jCyte, KalVista, Novartis, Ophthotech, Regeneron, Regenxbio, Stealth BioTherapeutics, TLC
Ownership Interest: Adverum, Aldeyra, Allegro, Aviceda, jCyte, Ocular Therapeutics

Dante J. Pieramici, MD
Consulting Fee: Adverum, Allegro, Gemini, Genentech, Novartis, Regeneron, Regenxbio
Contracted Research: Adverum, Apellis, Gemini, Genentech, Greybug, Ionis, Kodiak, Novartis, Opthea, Regeneron, Regenxbio, Stealth BioTherapeutics
Ownership Interest: Gemini

Carl D. Regillo, MD, FACS
Consulting Fee: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Kodiak, Merck, Notal Vision, Novartis, Takeda
Contracted Research: Adverum, Allergan, Chengdu Kanghong, Genentech, Graybug, Kodiak, Notal Vision, Novartis, Regeneron, Regenxbio

Charles C. Wykoff, MD, PhD
Consulting Fee: Acucela, Adverum, Alimera, Allegro, Allergan, Apellis, Bayer, Chengdu Kanghong, Clearside, DORC, EyePoint, Genentech/Roche, Iveric Bio, Kodiak, Merck, Neurotech, Novartis, ONL Therapeutics, Oxurion, PolyPhotonix, Recens Medical, Regeneron, Regenxbio
Speakers Bureau: Regeneron
Contracted Research: Adverum, Aerie, Allergan, Apellis, Chengdu Kanghong, Clearside, Gemini Therapeutics, Genentech/Roche, Graybug Vision, Ionis Pharmaceuticals, Iveric Bio, Kodiak, Neurotech, Novartis, Opthea, Optos, Outlook Therapeutics, Recens Medical, Regeneron, Regenxbio, Samsung, Santen

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.


Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)-approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.


Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2020 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.


CME Questions?

Contact us at cme@vindicoCME.com